Lu ZD - Search Results

1

Lipid-assisted PEG-b-PLA nanoparticles with ultrahigh SN38 loading capability for efficient cancer therapy.

Huang X, Li J, Yang Y, Wang ZL, Yang XZ, Lu ZD, Xu CF. Huang X, et al. Among authors: lu zd. Biomater Sci. 2023 Nov 7;11(22):7445-7457. doi: 10.1039/d3bm01469j. Biomater Sci. 2023. PMID: 37819252

2

Optimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammation.

Liu Y, Cao ZT, Xu CF, Lu ZD, Luo YL, Wang J. Liu Y, et al. Among authors: lu zd. Biomaterials. 2018 Jul;172:92-104. doi: 10.1016/j.biomaterials.2018.04.052. Epub 2018 Apr 26. Biomaterials. 2018. PMID: 29723758

3

Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy.

Liu Y , Zhao G , Xu CF , Luo YL , Lu ZD , Wang J . Liu Y , et al. Among authors: lu zd. Biomater Sci. 2018 May 29;6(6):1592-1603. doi: 10.1039/c8bm00263k. Biomater Sci. 2018. PMID: 29725684

4

Dually regulating the proliferation and the immune microenvironment of melanoma via nanoparticle-delivered siRNA targeting onco-immunologic CD155.

Wang Y , Luo YL , Chen YF , Lu ZD , Wang Y , Czarna A , Shen S , Xu CF , Wang J . Wang Y , et al. Among authors: lu zd. Biomater Sci. 2020 Dec 7;8(23):6683-6694. doi: 10.1039/d0bm01420f. Epub 2020 Oct 22. Biomater Sci. 2020. PMID: 33089844

5

Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.

Lu ZD, Chen YF, Shen S, Xu CF, Wang J. Lu ZD, et al. ACS Appl Mater Interfaces. 2021 Jun 30;13(25):29424-29438. doi: 10.1021/acsami.1c08329. Epub 2021 Jun 15. ACS Appl Mater Interfaces. 2021. PMID: 34129318

6

Optimized Cationic Lipid-assisted Nanoparticle for Delivering CpG Oligodeoxynucleotides to Treat Hepatitis B Virus Infection.

Chen YF, Wang Y, Wang Y, Luo YL, Lu ZD, Du XJ, Xu CF, Wang J. Chen YF, et al. Among authors: lu zd. Pharm Res. 2023 Jan;40(1):145-156. doi: 10.1007/s11095-022-03307-w. Epub 2022 Aug 24. Pharm Res. 2023. PMID: 36002611

7

Delivery of mRNA for regulating functions of immune cells.

Shi J, Huang MW, Lu ZD, Du XJ, Shen S, Xu CF, Wang J. Shi J, et al. Among authors: lu zd. J Control Release. 2022 May;345:494-511. doi: 10.1016/j.jconrel.2022.03.033. Epub 2022 Mar 23. J Control Release. 2022. PMID: 35337940 Free PMC article. Review.

8

An All-in-One Nanomedicine Consisting of CRISPR-Cas9 and an Autoantigen Peptide for Restoring Specific Immune Tolerance.

Luo YL, Liang LF, Gan YJ, Liu J, Zhang Y, Fan YN, Zhao G, Czarna A, Lu ZD, Du XJ, Shen S, Xu CF, Lian ZX, Wang J. Luo YL, et al. Among authors: lu zd. ACS Appl Mater Interfaces. 2020 Oct 28;12(43):48259-48271. doi: 10.1021/acsami.0c10885. Epub 2020 Oct 19. ACS Appl Mater Interfaces. 2020. PMID: 33070614

9

Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy.

Wang Y, Zhou SK, Wang Y, Lu ZD, Zhang Y, Xu CF, Wang J. Wang Y, et al. Among authors: lu zd. Nat Commun. 2023 Apr 8;14(1):1993. doi: 10.1038/s41467-023-37656-w. Nat Commun. 2023. PMID: 37031188 Free PMC article.

10

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases.

Xu C, Lu Z, Luo Y, Liu Y, Cao Z, Shen S, Li H, Liu J, Chen K, Chen Z, Yang X, Gu Z, Wang J. Xu C, et al. Nat Commun. 2018 Oct 5;9(1):4092. doi: 10.1038/s41467-018-06522-5. Nat Commun. 2018. PMID: 30291237 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters